Preconditioning protects the heart in a prolonged uremic condition

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 303, Issue 10, 2012, Pages

  Kocsis, Gabriella F ^a   Sárközy, Márta ^a   Bencsik, Péter ^b   Pipicz, Márton ^a   Varga, Zoltán V ^a   Pálóczi, János ^a   Csonka, Csaba ^a,b   Ferdinandy, Péter ^b,c   Csont, Tamás ^a,b  

^a UNIVERSITY OF SZEGED   (Hungary)

^b PHARMAHUNGARY GROUP   (Hungary)

^c SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Chronic renal failure; Infarct size; Ischemic preconditioning; Myocardial function; Myocardium

Indexed keywords

3 NITROTYROSINE; ANGIOTENSIN II; CREATININE; HEMOGLOBIN; UREA; URIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEART FUNCTION; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART PROTECTION; HEMATOCRIT; HEMOGLOBIN DETERMINATION; ISCHEMIC PRECONDITIONING; ISOLATED HEART; NEPHRECTOMY; NONHUMAN; PRIORITY JOURNAL; PROTEIN URINE LEVEL; RAT; REPERFUSION INJURY; TRANSTHORACIC ECHOCARDIOGRAPHY; ULTRASOUND; ULTRASOUND TRANSDUCER; UREMIA; URIC ACID BLOOD LEVEL;

ANGIOTENSIN II; ANIMALS; BIOLOGICAL MARKERS; CREATININE; DISEASE MODELS, ANIMAL; ISCHEMIC PRECONDITIONING, MYOCARDIAL; MALE; MYOCARDIAL CONTRACTION; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; NEPHRECTOMY; PROTEINURIA; RATS; RATS, WISTAR; STROKE VOLUME; TIME FACTORS; TYROSINE; UREA; UREMIA; URIC ACID; VENTRICULAR FUNCTION, LEFT;

EID: 84869071361     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00379.2012     Document Type: Article

References (59)

1. Bai Y, Sigala W, Adams GR, Vaziri ND. Effect of exercise on cardiac tissue oxidative and inflammatory mediators in chronic kidney disease. Am J Nephrol 29: 213-221, 2009.
2. Banerjee D, Ma JZ, Collins AJ, Herzog CA. Long-term survival of incident hemodialysis patients who are hospitalized for congestive heart failure, pulmonary edema, or fluid overload. Clin J Am Soc Nephrol 2: 1186-1190, 2007.
3. Boengler K, Konietzka I, Buechert A, Heinen Y, Garcia-Dorado D, Heusch G, Schulz R. Loss of ischemic preconditioning's cardioprotection in aged mouse hearts is associated with reduced gap junctional and mitochondrial levels of connexin 43. Am J Physiol Heart Circ Physiol 292: H1764-H1769, 2007.
4. Byrne CJ, McCafferty K, Kieswich J, Harwood S, Andrikopoulos P, Raftery M, Thiemermann C, Yaqoob MM. Ischemic conditioning protects the uremic heart in a rodent model of myocardial infarction. Circulation 125: 1256-1265, 2012.
5. Coritsidis GN, Linden E, Stern AS. The role of the primary care physician in managing early stages of chronic kidney disease. Postgrad Med 123: 177-185, 2011.
6. Csonka C, Kupai K, Kocsis GF, Novak G, Fekete V, Bencsik P, Csont T, Ferdinandy P. Measurement of myocardial infarct size in preclinical studies. J Pharmacol Toxicol Methods 61: 163-170, 2010.
7. Csont T, Csonka C, Onody A, Gorbe A, Dux L, Schulz R, Baxter GF, Ferdinandy P. Nitrate tolerance does not increase production of peroxynitrite in the heart. Am J Physiol Heart Circ Physiol 283: H69-H76, 2002.
8. Csont T, Ferdinandy P. Letter by Csont and Ferdinandy regarding article, "Ischemic conditioning protects the uremic heart in a rodent model of myocardial infarction". Circulation 126: e212, 2012.
9. Csont T, Szilvassy Z, Fulop F, Nedeianu S, Pali T, Tosaki A, Dux L, Ferdinandy P. Direct myocardial anti-ischaemic effect of GTN in both nitrate-tolerant and nontolerant rats: a cyclic GMP-independent activation of KATP. Br J Pharmacol 128: 1427-1434, 1999.
10. Dikow R, Kihm LP, Zeier M, Kapitza J, Tornig J, Amann K, Tiefenbacher C, Ritz E. Increased infarct size in uremic rats: reduced ischemia tolerance? J Am Soc Nephrol 15: 1530-1536, 2004.
11. Dunn SR, Qi Z, Bottinger EP, Breyer MD, Sharma K. Utility of endogenous creatinine clearance as a measure of renal function in mice. Kidney Int 65: 1959-1967, 2004.
12. Ebrahim Z, Yellon DM, Baxter GF. Attenuated cardioprotective response to bradykinin, but not classical ischaemic preconditioning, in DOCA-salt hypertensive left ventricular hypertrophy. Pharmacol Res 55: 42-48, 2007.
13. Ebrahim Z, Yellon DM, Baxter GF. Ischemic preconditioning is lost in aging hypertensive rat heart: independent effects of aging and longstanding hypertension. Exp Gerontol 42: 807-814, 2007.
14. Ferdinandy P, Csonka C, Csont T, Szilvassy Z, Dux L. Rapid pacinginduced preconditioning is recaptured by farnesol treatment in hearts of cholesterol-fed rats: role of polyprenyl derivatives and nitric oxide. Mol Cell Biochem 186: 27-34, 1998.
15. Ferdinandy P, Schulz R, Baxter GF. Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning. Pharmacol Rev 59: 418-458, 2007.
16. Ferdinandy P, Szilvassy Z, Baxter GF. Adaptation to myocardial stress in disease states: is preconditioning a healthy heart phenomenon? Trends Pharmacol Sci 19: 223-229, 1998.
17. Ferdinandy P, Szilvassy Z, Horvath LI, Csont T, Csonka C, Nagy E, Szentgyorgyi R, Nagy I, Koltai M, Dux L. Loss of pacing-induced preconditioning in rat hearts: role of nitric oxide and cholesterol-enriched diet. J Mol Cell Cardiol 29: 3321-3333, 1997.
18. Foley RN, Murray AM, Li S, Herzog CA, McBean AM, Eggers PW, Collins AJ. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol 16: 489-495, 2005.
19. Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 9, Suppl 12: S16-S23, 1998
20. Gavras I, Gavras H. Angiotensin II as a cardiovascular risk factor. J Hum Hypertens 16, Suppl 2: S2-S6, 2002.
21. Gerczuk PZ, Kloner RA. Protecting the heart from ischemia: an update on ischemic and pharmacologic conditioning. Hosp Pract (Minneap) 39: 35-43, 2011.
22. Ghosh S, Standen NB, Galinianes M. Failure to precondition pathological human myocardium. J Am Coll Cardiol 37: 711-718, 2001.
23. Giricz Z, Lalu MM, Csonka C, Bencsik P, Schulz R, Ferdinandy P. Hyperlipidemia attenuates the infarct size-limiting effect of ischemic preconditioning: role of matrix metalloproteinase-2 inhibition. J Pharmacol Exp Ther 316: 154-161, 2006.
24. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351: 1296-1305, 2004.
25. 1 receptor in remnant kidney: strong renoprotection by therapy with losartan and a nonsteroidal anti-inflammatory. Am J Physiol Renal Physiol 286: F945-F954, 2004.
26. Herzog CA, Ma JZ, Collins AJ. Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N Engl J Med 339: 799-805, 1998.
27. 1) receptor blockers in hypertension. J Hum Hypertens 14, Suppl 1: S73-S86, 2000.
28. Jin Y, Kuznetsova T, Thijs L, Schmitz B, Liu Y, Asayama K, Brand SM, Heymans S, Brand E, Fagard R, Staessen JA. Association of left ventricular mass with the AGTR1 A1166C polymorphism. Am J Hypertens 25: 472-478, 2012.
29. Kasiske BL, O'Donnell MP, Garvis WJ, Keane WF. Pharmacologic treatment of hyperlipidemia reduces glomerular injury in rat 5/6 nephrectomy model of chronic renal failure. Circ Res 62: 367-374, 1988.
30. Kitakaze M, Hori M. It is time to ask what adenosine can do for cardioprotection. Heart Vessels 13: 211-228, 1998.
31. Kocsis GF, Pipis J, Fekete V, Kovacs-Simon A, Odendaal L, Molnar E, Giricz Z, Janaky T, van Rooyen J, Csont T, Ferdinandy P. Lovastatin interferes with the infarct size-limiting effect of ischemic preconditioning and postconditioning in rat hearts. Am J Physiol Heart Circ Physiol 294: H2406-H2409, 2008.
32. Kocsisne GF, Bencsik P, Fekete V, Varga ZV, Monostori P, Turi S, Ferdinandy P, Csont T. The influence of chronic renal failure on the cardioprotective effect of postconditioning in rats with partial nephrectomy (Abstract). Cardiovasc Res 87, Suppl 1: S135, 2010.
33. Koleganova N, Piecha G, Ritz E, Bekeredjian R, Schirmacher P, Schmitt CP, Gross ML. Interstitial fibrosis and microvascular disease of the heart in uremia: amelioration by a calcimimetic. Lab Invest 89: 520-530, 2009.
34. Kopecky SL, Aviles RJ, Bell MR, Lobl JK, Tipping D, Frommell G, Ramsey K, Holland AE, Midei M, Jain A, Kellett M, Gibbons RJ, AmP579 Delivery for Myocardial Infarction REduction study. A randomized, double-blinded, placebo-controlled, dose-ranging study measuring the effect of an adenosine agonist on infarct size reduction in patients undergoing primary percutaneous transluminal coronary angioplasty: the ADMIRE (AmP579 Delivery for Myocardial Infarction REduction) study. Am Heart J 146: 146-152, 2003.
35. Kristiansen SB, Lofgren B, Stottrup NB, Khatir D, Nielsen-Kudsk JE, Nielsen TT, Botker HE, Flyvbjerg A. Ischaemic preconditioning does not protect the heart in obese and lean animal models of type 2 diabetes. Diabetologia 47: 1716-1721, 2004.
36. Kupai K, Csonka C, Fekete V, Odendaal L, van Rooyen J, Marais de W, Csont T, Ferdinandy P. Cholesterol diet-induced hyperlipidemia impairs the cardioprotective effect of postconditioning: role of peroxynitrite. Am J Physiol Heart Circ Physiol 297: H1729-H1735, 2009.
37. Levey AS, Coresh J. Chronic kidney disease. Lancet 379: 165-180, 2012.
38. Li Y, Takemura G, Okada H, Miyata S, Maruyama R, Esaki M, Kanamori H, Li L, Ogino A, Ohno T, Kondo T, Nakagawa M, Minatoguchi S, Fujiwara T, Fujiwara H. Molecular signaling mediated by angiotensin II type 1A receptor blockade leading to attenuation of renal dysfunction-associated heart failure. J Card Fail 13: 155-162, 2007.
39. Liu J, Rigel DF. Echocardiographic examination in rats and mice. Methods Mol Biol 573: 139-155, 2009.
40. Lynch KM, Sellers TS, Gossett KA. Evaluation of an automated pyrogallol red-molybdate method for the measurement of urinary protein in rats. Eur J Clin Chem Clin Biochem 34: 569-571, 1996.
41. Michea L, Villagran A, Urzua A, Kuntsmann S, Venegas P, Carrasco L, Gonzalez M, Marusic ET. Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and prevents oxidative stress in uremic rats. Hypertension 52: 295-300, 2008.
42. Morrison AB, Howard RM. The functional capacity of hypertrophied nephrons. Effect of partial nephrectomy on the clearance of inulin and PAH in the rat. J Exp Med 123: 829-844, 1966.
43. Munger MA. Use of angiotensin receptor blockers in cardiovascular protection: current evidence and future directions. P T 36: 22-40, 2011.
44. Ovize M, Baxter GF, Di Lisa F, Ferdinandy P, Garcia-Dorado D, Hausenloy DJ, Heusch G, Vinten-Johansen J, Yellon DM, Schulz R, Working Group of Cellular Biology of Heart of European Society of Cardiology. Postconditioning and protection from reperfusion injury: where do we stand? Position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology. Cardiovasc Res 87: 406-423, 2010.
45. Pantos CI, Davos CH, Carageorgiou HC, Varonos DV, Cokkinos DV. Ischaemic preconditioning protects against myocardial dysfunction caused by ischaemia in isolated hypertrophied rat hearts. Basic Res Cardiol 91: 444-449, 1996.
46. 2) on myocardial ischemia-reperfusion induced infarct size. Cytokine 56: 688-694, 2011.
47. Przyklenk K, Maynard M, Darling CE, Whittaker P. Aging mouse hearts are refractory to infarct size reduction with post-conditioning. J Am Coll Cardiol 51: 1393-1398, 2008.
48. Przyklenk K, Maynard M, Greiner DL, Whittaker P. Cardioprotection with postconditioning: loss of efficacy in murine models of type-2 and type-1 diabetes. Antioxid Redox Signal 14: 781-790, 2011.
49. Rezkalla SH, Kloner RA. Preconditioning in humans. Heart Fail Rev 12: 201-206, 2007.
50. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, Wilson PW, American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 108: 2154-2169, 2003.
51. Sindhu RK, Ehdaie A, Vaziri ND, Roberts CK. Effects of chronic renal failure on caveolin-1, guanylate cyclase and AKT protein expression. Biochim Biophys Acta 1690: 3: 231-237, 2004.
52. Speechly-Dick ME, Baxter GF, Yellon DM. Ischaemic preconditioning protects hypertrophied myocardium. Cardiovasc Res 28: 1025-1029, 1994
53. Stack AG, Bloembergen WE. A cross-sectional study of the prevalence and clinical correlates of congestive heart failure among incident US dialysis patients. Am J Kidney Dis 38: 992-1000, 2001.
54. Tosaki A, Engelman DT, Engelman RM, Das DK. The evolution of diabetic response to ischemia/reperfusion and preconditioning in isolated working rat hearts. Cardiovasc Res 31: 526-536, 1996.
55. Ungi I, Ungi T, Ruzsa Z, Nagy E, Zimmermann Z, Csont T, Ferdinandy P. Hypercholesterolemia attenuates the anti-ischemic effect of preconditioning during coronary angioplasty. Chest 128: 1623-1628, 2005
56. Vaziri ND. Effect of chronic renal failure on nitric oxide metabolism. Am J Kidney Dis 38, Suppl 1: S74-S79, 2001.
57. Vaziri ND, Ni Z, Oveisi F, Liang K, Pandian R. Enhanced nitric oxide inactivation and protein nitration by reactive oxygen species in renal insufficiency. Hypertension 39: 135-141, 2002.
58. Wright JW, Mizutani S, Harding JW. Pathways involved in the transition from hypertension to hypertrophy to heart failure. Treatment strategies. Heart Fail Rev 13: 367-375, 2008.
59. Zheng J, Chin A, Duignan I, Won KH, Hong MK, Edelberg JM. Growth factor-mediated reversal of senescent dysfunction of ischemiainduced cardioprotection. Am J Physiol Heart Circ Physiol 290: H525-H530, 2006.